Adcetris (Brentuximab Vedotin)

This is a type of medicine used to treat certain types of lymphoma, which is a cancer of the lymphatic system. It works by targeting a specific protein found on lymphoma cells.

Brand names:Adcetris
Medication

What people taking Adcetris (Brentuximab Vedotin) report

Every report comes from a Lived member, sent anonymously.

Have you tried Adcetris (Brentuximab Vedotin) for Hodgkin Lymphoma?

NameHow it went

About Adcetris (Brentuximab Vedotin)

What It's For

Brentuximab vedotin, sold under the brand name Adcetris, is a targeted cancer medicine for several types of lymphoma, cancers that begin in infection-fighting white blood cells. It is built to find lymphoma cells that carry a protein called CD30 on their surface. CD30 is characteristic of classical Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL), and it appears in some other T-cell lymphomas. In classical Hodgkin lymphoma, adults with newly diagnosed stage III or IV disease can receive it with three chemotherapy drugs (doxorubicin, vinblastine and dacarbazine, a combination called A+AVD). Children 2 and older with newly diagnosed high-risk Hodgkin lymphoma can receive it with a five-drug chemotherapy combination. Adults also receive it on its own after an autologous stem cell transplant (a transplant using their own stem cells), either to lower the chance of relapse when that risk is high or to treat lymphoma that has come back. It is also an option when Hodgkin lymphoma returns after at least two chemotherapy combinations in someone who cannot have a transplant. For T-cell lymphomas, adults with newly diagnosed systemic ALCL or other peripheral T-cell lymphomas that carry CD30 can receive it with cyclophosphamide, doxorubicin and prednisone. It is used alone for systemic ALCL that returns after chemotherapy, and for two lymphomas that mainly affect the skin, primary cutaneous ALCL and CD30-positive mycosis fungoides, in adults who have already had treatment that works throughout the body. It is also approved with lenalidomide (a cancer medicine taken by mouth) and rituximab (an antibody treatment for B-cell lymphomas) for adults with large B-cell lymphoma, including diffuse large B-cell lymphoma, that has returned or not responded after two or more earlier treatments, when a stem cell transplant or CAR T-cell therapy (a treatment made from a person's own engineered immune cells) is not an option.

How It Works

Brentuximab vedotin is an antibody-drug conjugate, a lab-made antibody joined to a potent cell-killing drug. The antibody part seeks out CD30, which sits on the surface of certain lymphoma cells but is found on relatively few healthy cells. Once the antibody latches on, the cell pulls the whole complex inside, where the attached drug, called MMAE (monomethyl auristatin E), is cut loose. MMAE disrupts microtubules, the internal scaffolding a cell needs in order to divide. Without that scaffolding, the lymphoma cell stops dividing and dies. Delivering the drug this way concentrates it where CD30 is, but it does not make treatment free of side effects: nerve damage and low blood counts are common, as described below.

Dosage & Administration

Brentuximab vedotin is given only as an intravenous (IV) infusion, a drip into a vein that takes about 30 minutes, at an infusion center or hospital. The dose is calculated from body weight, with the calculation capped at 100 kg (about 220 pounds). The schedule depends on the regimen: every two weeks alongside AVD chemotherapy for adult Hodgkin lymphoma, and every three weeks in most other uses. Some courses have a set length, such as up to 12 doses with AVD, up to 16 doses after a transplant, or 6 to 8 doses with chemotherapy for T-cell lymphoma. When it is used alone for lymphoma that has come back, it can continue as long as the lymphoma is controlled and side effects remain manageable. When it is combined with chemotherapy, or with lenalidomide and rituximab, people also receive G-CSF (a growth factor injection that helps the bone marrow make infection-fighting white blood cells) starting with the first cycle. Blood counts are checked before every dose, and the team may delay, lower or stop doses if nerve problems or low blood counts develop.

Side Effects

The most common side effects are nerve damage, nausea, tiredness, muscle and joint pain, constipation, diarrhea, vomiting, fever, colds and other upper respiratory infections, mouth sores, belly pain and rash. Peripheral neuropathy, damage to the nerves of the hands and feet, is the side effect most likely to shape treatment. It builds up with each dose and usually shows up as numbness, tingling, burning or pain, sometimes with muscle weakness. About 6 in 10 people who took the drug alone developed some degree of it, often two to three months in. Many improve over the following months, but for some it does not fully go away. Report symptoms early, because the team can delay or lower doses before the damage becomes severe. The drug can lower white blood cell counts, which raises the risk of serious and sometimes fatal infections. Call the care team right away for a fever of 100.5°F (38°C) or higher, chills, a new cough or pain when urinating, and check with them before taking medicine to bring a fever down, since it can hide signs of infection. Infusion reactions, including severe allergic reactions (anaphylaxis), can happen during a dose; the infusion staff monitor for them and stop the drip if one occurs. People who have had a reaction usually receive acetaminophen, an antihistamine and a steroid before later doses. Fever, chills, rash or breathing problems within 24 hours of an infusion should be reported to the care team. Less common problems can be serious. Contact the care team right away about severe belly pain, which can signal pancreatitis or a bowel complication. Also report a new or worsening cough or shortness of breath (possible lung inflammation), yellowing skin or eyes, dark urine or discomfort in the upper right belly (possible liver injury), and any blistering or peeling rash. Blood sugar can rise, sometimes sharply, especially in people with diabetes or a higher body weight; unusual thirst, frequent urination or blurred vision are worth reporting.

Interactions & Warnings

Brentuximab vedotin carries a boxed warning, the FDA's most serious label warning, about progressive multifocal leukoencephalopathy (PML). PML is a rare brain infection caused by the JC virus, and it has caused deaths in people taking this drug. Earlier treatments and the lymphoma itself, both of which can weaken the immune system, may add to the risk. Contact the care team immediately about new confusion, memory or thinking problems, changes in mood or behavior, changes in vision, speech or walking, or weakness on one side of the body. These changes are sometimes noticed first by family members, and their observations count too. It must never be given together with bleomycin, a chemotherapy drug used in some older Hodgkin lymphoma regimens, because the combination caused lung toxicity. Regimens that include brentuximab vedotin leave bleomycin out. Strong blockers of CYP3A4, a liver enzyme that breaks down many drugs, can raise levels of the drug's MMAE component and make side effects more likely. Ketoconazole, an antifungal, is one example. Give the care team a full list of medicines and supplements, including anything newly prescribed by another clinician. The drug is avoided in people with severe kidney impairment or moderate to severe liver impairment, because serious side effects and deaths were more frequent in those groups. Mild liver impairment calls for a lower dose, and existing liver disease raises the chance of liver injury during treatment. Brentuximab vedotin can harm a developing baby, so a pregnancy test is done before starting when relevant. Women who could become pregnant should use effective birth control during treatment and for 2 months after the last dose, and men with partners who could become pregnant should use it for 4 months after the last dose. Tell the care team right away about a pregnancy. Breastfeeding is not recommended during treatment. The drug may also affect fertility in both women and men, which is worth discussing before treatment begins.

What to Expect

Treatment is managed by an oncologist or hematologist (a doctor who specializes in cancer or blood disorders) as part of a defined plan. A typical visit includes blood tests, questions about nerve symptoms and the 30-minute infusion, plus time for any other drugs given the same day. Blood sugar and liver tests are checked along the way, and scans and examinations show whether the lymphoma is responding. The evidence for benefit depends on the lymphoma and the setting. In a trial of more than 1,300 adults with advanced Hodgkin lymphoma, people treated with A+AVD were more likely to be alive after about six years than those treated with the older ABVD regimen, which uses bleomycin in place of brentuximab vedotin. In newly diagnosed CD30-positive peripheral T-cell lymphoma, adding it to chemotherapy more than doubled the typical time before the lymphoma worsened: half of people were still free of progression at about 48 months, compared with about 21 months on the standard CHOP chemotherapy. After a transplant for high-risk Hodgkin lymphoma, it delayed relapse compared with no further treatment, although it had not been shown to help people live longer at the time of that analysis. Tiredness and stomach side effects tend to come and go with the treatment cycle, while nerve symptoms build gradually. After the last dose, most side effects ease, but neuropathy can take months to improve and may not fully resolve. Follow-up visits continue after treatment to watch for lymphoma returning and for lingering effects.

Questions to Ask Your Doctor

  1. 1.Why is brentuximab vedotin recommended for my type of lymphoma, and what would the alternatives be?
  2. 2.Is the goal of this treatment cure, preventing relapse or keeping the lymphoma under control, and how will we know it is working?
  3. 3.How many doses am I likely to receive, and what will we do if numbness or tingling starts?
  4. 4.Who do I call for a fever or new symptoms outside clinic hours?
  5. 5.What do I need to know about birth control, pregnancy and fertility before starting?

Last reviewed • Oct 2026

Educational content, not medical advice.